Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (4): 631-635. doi: 10.19723/j.issn.1671-167X.2023.04.010

Previous Articles     Next Articles

Significance of IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 antibody in rheumatoid arthritis

Yin-ji JIN,Lin SUN,Jin-xia ZHAO*(),Xiang-yuan LIU   

  1. Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China
  • Received:2020-07-31 Online:2023-08-18 Published:2023-08-03
  • Contact: Jin-xia ZHAO E-mail:zhao-jinxia@163.com
  • Supported by:
    the National Natural Science Foundation of China(81273293);the Seed Foundation of Peking University Third hospital(Y87473-01)

RICH HTML

  

Abstract:

Objective: To detect serum IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 (BRAF) antibody levels in the rheumatoid arthritis (RA) patients in order to investigate their clinical significance in RA. Methods: Serum samples were obtained from 61 RA patients, 21 osteoarthritis (OA) patients, 16 systemic lupus erythematosus (SLE) patients, 16 gout patients, 16 Sjögren's syndrome (SS) patients and 22 healthy controls. IgA isotype of anti-BRAF antibody levels in the sera were examined by enzyme-linked immunosorbent assay (ELISA). The associations between IgA isotype of anti-BRAF antibody levels and the clinical features including age, disease duration and laboratory parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score in 28 joints (DAS28), anti-cyclic citrullinated peptide (anti-CCP) antibody, immunoglobulin and BRAF protein levels in the RA patients were evaluated. Data analyses were performed by using SPSS 19.0 program. Results: The serum IgA isotype of anti-BRAF antibody levels in the RA patients were significantly higher than in the SLE, gout, OA patients and healthy controls, the P value was 0.011, < 0.001, < 0.001 and < 0.001, respectively. The serum IgA isotype of anti-BRAF antibody levels in the SS patients were also significantly higher than in the SLE, gout, OA patients and healthy controls, the P value was 0.029, 0.004, 0.001 and < 0.001, respectively. However, there was no difference between the RA and SS patients (P=0.762). IgA isotype of anti-BRAF antibody was measurable in the RA patients without RF, anti-CCP antibody or anti-keratin antibody (AKA) antibodies. The levels of IgA isotype of anti-BRAF antibody in the RA patients did not show any correlation with clinical features such as age and disease duration or laboratory parameters including ESR, CRP, RF, DAS28, anti-CCP antibody, immunoglobulin and BRAF protein levels. Compared with the clinical features and laboratory indexes of normal and elevated levels of IgA isotype of anti-BRAF antibody groups in the RA patients, there was no significant differences between the two groups in age, disease duration, ESR, CRP, RF, DAS28, anti-CCP antibody, immunoglobulin or BRAF protein levels. Conclusion: The elevated level of IgA isotype of anti-BRAF antibody in the RA patients showed that IgA isotype of anti-BRAF antibody might play a role in the pathogenesis of RA. Furthermore, detection of IgA isotype of anti-BRAF antibody in the serum negative RA patients showed that it might be helpful for the diagnosis of the serum negative RA patients.

Key words: Rheumatoid arthritis, v-raf murine sarcoma viral oncogene homologue B1, IgA isotype of anti-BRAF antibody

CLC Number: 

  • R593.22

Table 1

The AU level of IgA isotype of anti-BRAF antibody in different disease groups"

Disease type n AU P value
RA 61 62.4±43.5
SS 16 65.6±35.6 0.762
SLE 16 37.0±21.3 0.011
Gout 16 29.1±22.9 < 0.001
OA 21 21.9±17.2 < 0.001
Normal control 22 15.2±22.0 < 0.001

Table 2

Correlation analysis between the level of IgA isotype of anti-BRAF antibody and laboratory indexes in the RA patients"

Clinical index Correlation coefficient P value
Age -0.026 0.858
Duration 0.253 0.079
DAS28 -0.048 0.760
CRP 0.010 0.946
ESR 0.088 0.555
RF 0.207 0.153
Anti-CCP 0.053 1.725
IgA 0.143 0.419
IgM 0.129 0.469
IgG -0.088 0.614
BRAF protein 0.153 0.292

Table 3

Comparison of laboratory indexes of positive and negative IgA isotype of anti-BRAF antibody in RA patients"

Clinical index Antibody positive group Antibody negative group P value
Age/years 53.4±13.5 52.6±15.9 0.848
Duration/months 60.0 (1.0-360.0) 33.0 (1.0-240.0) 0.335
DAS28 4.56±1.27 4.60±0.62 0.879
CRP/(mg/dL) 2.11 (0.11-16.60) 2.58 (0.11-8.89) 0.818
ESR/(mm/h) 41.5 (2.0-110.0) 42.0 (6.0-84.0) 0.907
RF/(IU/mL) 115.0 (10.0-1 860.0) 50.0 (10.0-1 890.0) 0.126
Anti-CCP/(U/mL) 135.0 (7.0-500.0) 100.0 (7.0-500.0) 1.003
IgA/(mg/L) 3 340±1 340 3 340±1 610 0.719
IgM/(mg/L) 1 140 (610-3 990) 1 130 (210-2 640) 0.885
IgG/(mg/L) 15 440±6 700 17 680±7 850 0.371
BRAF protein/(ng/L) 9 557.5±8 208.9 6 865.6±5 368.4 0.196
1 Ikawa S , Fukui M , Ueyama Y , et al. B-raf, a new member of the raf family is activated by DNA rearrangement[J]. Mol Cell Biol, 1988, 8 (6): 2651- 2654.
2 Karhryn I . Raf protiens and cancer: B-Raf is identified as a mutational target[J]. Biochim Biophys Acta, 2003, 1653 (1): 25- 40.
3 Luo SF , Fang RY , Hsieh HL , et al. Involvement of MAPKs and NF-kappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule l expression in human rheumatoid arthritis synovial fibroblasts[J]. Arthritis Rheum, 2010, 62 (1): 105- 116.
doi: 10.1002/art.25060
4 Schett G , Zwerina J , Firestein G . The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis[J]. Ann Rheum Dis, 2008, 67 (7): 909- 916.
doi: 10.1136/ard.2007.074278
5 Auger I , Balandraud N , Rak J , et al. New autoantigens in rheumatoid arthritis (RA): Screening 8268 protein arrays with sera from patients with RA[J]. Ann Rheum Dis, 2009, 68 (4): 591- 594.
doi: 10.1136/ard.2008.096917
6 Szekanecz Z , Soós L , Szabó Z , et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: As good as it gets?[J]. Clin Rev Allergy Immunol, 2008, 34 (1): 26- 31.
doi: 10.1007/s12016-007-8022-5
7 Wang XP , Cheng QY , Gu MM , et al. Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: A meta-analysis[J]. Clin Rheumatol, 2019, 38 (7): 1841- 1849.
doi: 10.1007/s10067-019-04464-x
8 Charpin C , Martin M , Balandraud N , et al. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis[J]. Arthritis Res Ther, 2010, 12 (5): R194.
doi: 10.1186/ar3165
9 张霞, 赵金霞, 孙琳, 等. 抗鼠科肉瘤病毒癌基因同源物B1抗体的检测及其在类风湿关节炎诊断中的意义[J]. 北京大学学报(医学版), 2012, 44 (2): 195- 198.
10 Woof JM , Mestecky J . Mucosal immunoglobulins[J]. Immunol Rev, 2005, 206, 64- 82.
doi: 10.1111/j.0105-2896.2005.00290.x
11 Thalhamer T , McGrath MA , Hamett MM . MAPKs and their relevance to arthritis and inflammation[J]. Rheumatology (Oxford), 2008, 47 (4): 409- 414.
[1] Hui WEI, Jingfeng ZHANG, Zhongqiang YAO, Jinxia ZHAO. Clinical characteristics and relevant factors of rheumatoid arthritis patients with anemia of chronic disease [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 307-312.
[2] Tao WU, Jianzi LIN, Yafeng ZHU, Jianda MA, Peiwen JIA, Lijuan YANG, jie PAN, Yaowei ZOU, Ying YANG, Ye LU, Lie DAI. Serum inter-alpha-trypsin inhibitor heavy chain H3 is identified as a potential biomarker for myopenia in patients with rheumatoid arthritis using proteomic profiling [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1024-1031.
[3] Yan DING, Lifang WANG, Chaoran LI, Zhemin LU, Lianjie SHI. Rheumatoid arthritis combined with IgG4-related disease successfully treated with rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1203-1207.
[4] Ju YANG, Jing XU, Juhua DAI, Lianjie SHI. Expression of lumican protein in serum of patients with rheumatoid arthritis and its correlation with disease and immune activities [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 911-918.
[5] Lianghua FENG, Lirong HONG, Yujia CHEN, Xueming CAI. Role and mechanism of ubiquitin-specific protease 35 in ferroptosis of rheumatoid arthritis-fibroblast like synoviocytes [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 919-925.
[6] Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016.
[7] Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114.
[8] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
[9] Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979.
[10] Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000.
[11] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[12] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[13] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[14] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[15] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!